Chemomab Therapeutics (CMMB) Short-term Investments (2018 - 2025)

Chemomab Therapeutics (CMMB) has 8 years of Short-term Investments data on file, last reported at $2.8 million in Q4 2025.

• For the quarter ending Q4 2025, Short-term Investments rose 3586.84% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (up 3586.84% YoY), and the FY2025 full-year result was $2.8 million, up 3586.84% from the prior year.
• Short-term Investments for Q4 2025 stood at $2.8 million, up from $149000.0 in the prior quarter.
• Across five years, Short-term Investments topped out at $43.6 million in Q1 2022 and bottomed at $23000.0 in Q1 2021.
• The 5-year median for Short-term Investments is $140000.0 (2025), against an average of $9.7 million.
• The widest annual swing landed in 2022, when Short-term Investments surged 189373.91%; it then sank 99.82% in 2023.
• A 5-year view of Short-term Investments shows it stood at $26.5 million in 2021, then sank by 99.71% to $77000.0 in 2022, then fell by 1.3% to $76000.0 in 2023, then changed by 0.0% to $76000.0 in 2024, then soared by 3586.84% to $2.8 million in 2025.
• The last three Short-term Investments figures came in at $2.8 million (Q4 2025), $149000.0 (Q3 2025), and $148000.0 (Q2 2025), per Business Quant data.

Peer Comparison